Alvotech (ALVO) investor relations material

Executive summary

• Achieved total revenues of $593 million in FY2025, up 21% year-over-year, with adjusted EBITDA of $137 million, a 27% increase, and gross margin at 61%.

• Expanded global biosimilar leadership with a pipeline of 30 biosimilars in development and commercial reach in 90 countries.

• Completed leadership transition with new CEO and key management roles now based in Iceland, focusing on operational execution and commercial scale.

• Significant investments in quality, compliance, manufacturing capacity, and R&D through acquisitions of Xbrane and Ivers-Lee.

• Strengthened balance sheet with $172 million cash at year-end, following nearly $300 million raised from capital markets and Nasdaq Stockholm listing.

Financial highlights

• FY2025 total revenues rose 21% year-over-year to $593 million, with adjusted EBITDA up 27% to $137 million (23% margin) and gross margin at 61%.

• Q4 2025 revenues increased 13% year-over-year to $173 million, with gross margin reaching 66%.

• Product revenues were $43 million in Q4, with negative product margin due to facility upgrades and order timing.

• Operating cash flow for 2025 was positive for the first time at $7 million; year-end cash balance was $172 million.

• Financing activities in Q4 included $108 million in convertible bonds and a $100 million senior term loan.

Outlook and guidance

• 2026 revenue guidance set at $650–$700 million, reflecting continued double-digit growth; lower end assumes no U.S. launches.

• Adjusted EBITDA expected at $180–$220 million, supported by portfolio expansion and operating scale.

• Revenue growth to be driven by momentum from existing launches in Europe, UK, Japan, and rest of world, with U.S. launches providing upside.

• Focus on reaching cash flow positivity by year-end 2026.

• U.S. approvals for four pending BLAs anticipated by late 2026, with minimal topline impact expected from potential delays.